At Ryvu we

Transform oncology therapy to enhance patient lives

Your Journey,
Our Commitment

We’re more than a biotechnology company—we’re a partner in your journey through cancer care. Whether you are the patient or a caregiver, we understand the road can be difficult. That’s why we’re working every day on innovative therapies that have a real impact on health and quality of life.

We are here to support you every step of the way on this journey.

Advancing Oncology with Innovative Therapies

Our mission is to develop cutting-edge cancer therapies that make a meaningful difference in patients’ lives. By targeting key pathways in cancer biology, we create precise, effective treatments that offer better outcomes and improved quality of life.

Driving Progress by Targeting Key Pathways

Ryvu Therapeutics is advancing a broad pipeline by addressing emerging targets in oncology. Our pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinase, synthetic lethality, and immuno-oncology pathways.

Our pipeline

RVU120 CDK8/19

R/R AML (RIVER-81)

RVU120 CDK8/19

Myelofibrosis (POTAMI-61)

RVU120 CDK8/19

LR-MDS (REMARK)

Dapolsertib
(MEN1703, SEL24, PIM/FLT3)

DLBCL (JASPIS-01)

RVU305 (MTA-cooperative PRMT5)

MTAP-deleted tumors

Discovery

Preclinical

Phase I

Phase II